Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma

Resident CD141 (BDCA3)+dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation

(2012) Chung-Ching Chu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

(2012) Erika von Euw et al.   Molecular Cancer

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

(2012) Alex Kentsis et al.   NATURE MEDICINE

MET: a promising anticancer therapeutic target

(2012) Solange Peters et al.   Nature Reviews Clinical Oncology

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Cancer Genetics With an Edge

(2012) J. Kaiser   SCIENCE

Tumor associated regulatory dendritic cells

(2012) Yang Ma et al.   SEMINARS IN CANCER BIOLOGY

Malignant Melanoma and Its Stromal Nonimmune Microecosystem

(2012) Gérald E. Piérard et al.   Journal of Oncology

Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics

(2011) Alvin J.X. Lee et al.   BIOCHEMICAL PHARMACOLOGY

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

(2011) J Lin et al.   BRITISH JOURNAL OF CANCER

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling

(2011) Melissa M. McKay et al.   CURRENT BIOLOGY

PLX4032 and melanoma: resistance, expectations and uncertainty

(2011) Dimitrios H Roukos   Expert Review of Anticancer Therapy

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

(2011) Gregor Hoermann et al.   FASEB JOURNAL

Latest developments in the treatment of melanoma: ‘a penicillin moment for cancer’?

(2011) Spyros Retsas   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer

(2011) Tadaaki Yamada et al.   Journal of Thoracic Oncology

Tumour evolution inferred by single-cell sequencing

(2011) Nicholas Navin et al.   NATURE

Forty years on from Nixon's war, cancer research 'evolves'

(2011) Nadia Drake   NATURE MEDICINE

BRAF targeted therapy changes the treatment paradigm in melanoma

(2011) Antoni Ribas et al.   Nature Reviews Clinical Oncology

Vemurafenib

(2011) Keith. T Flaherty et al.   NATURE REVIEWS DRUG DISCOVERY

Resistance to BRAF Inhibition in Melanomas

(2011) David B. Solit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combining Targeted Drugs to Stop Resistant Tumors

(2011) J. Kaiser   SCIENCE

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

(2010) F M Kaplan et al.   ONCOGENE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Interactions in Chondroitin 4-Sulfate Mediated Adherence ofPlasmodium falciparumInfected Erythrocytes in Human Placenta during Pregnancy-Associated Malaria†

(2008) Rajeshwara N. Achur et al.   BIOCHEMISTRY

The “seed and soil” hypothesis revisited

(2008) Isaiah J Fidler et al.   LANCET ONCOLOGY